C4 Therapeutics, Inc.CCCCEarnings & Financial Report
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.
Revenue
$3.0M
Gross Profit
N/A
Operating Profit
$-32.2M
Net Profit
$-28.4M
Gross Margin
N/A
Operating Margin
-1060.2%
Net Margin
-933.2%
YoY Growth
-19.2%
EPS
$-0.41
C4 Therapeutics, Inc. Q1 FY2024 Financial Summary
C4 Therapeutics, Inc. reported revenue of $3.0M (down 19.2% YoY) for Q1 FY2024, with a net profit of $-28.4M (up 18.5% YoY) (-933.2% margin).
Key Financial Metrics
| Total Revenue | $3.0M |
|---|---|
| Net Profit | $-28.4M |
| Gross Margin | N/A |
| Operating Margin | -1060.2% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
C4 Therapeutics, Inc. Q1 FY2024 revenue of $3.0M breaks down across 2 segments, led by Other at $1.6M (51.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $1.6M | 51.0% |
| Roche Agreement | $1.5M | 49.0% |
C4 Therapeutics, Inc. Revenue by Segment — Quarterly Trend
C4 Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Roche Agreement) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | — | $2.0M | — | $460.0K |
| Roche Agreement | — | — | $1.9M | $2.5M |
C4 Therapeutics, Inc. Annual Revenue by Year
C4 Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $35.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $35.9M |
| 2024 | $35.6M |
| 2023 | $20.8M |
| 2022 | $31.1M |
C4 Therapeutics, Inc. Quarterly Revenue & Net Profit History
C4 Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.0M | +112.8% | $-20.5M | -186.0% |
| Q3 FY2025 | $11.2M | -26.9% | $-32.2M | -286.4% |
| Q2 FY2025 | $6.5M | -46.2% | $-26.0M | -402.6% |
| Q1 FY2025 | $7.2M | +138.2% | $-26.3M | -363.7% |
| Q4 FY2024 | $5.2M | +58.8% | $-34.6M | -667.8% |
| Q3 FY2024 | $15.4M | +38.7% | $-24.7M | -160.6% |
| Q2 FY2024 | $12.0M | +350.7% | $-17.7M | -147.6% |
| Q1 FY2024 | $3.0M | -19.2% | $-28.4M | -933.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $12.0M | $15.4M | $5.2M | $7.2M | $6.5M | $11.2M | $11.0M |
| YoY Growth | -19.2% | 350.7% | 38.7% | 58.8% | 138.2% | -46.2% | -26.9% | 112.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $398.4M | $381.1M | $376.1M | $349.6M | $319.5M | $296.5M | $265.5M | $359.1M |
| Liabilities | $140.1M | $134.0M | $133.4M | $133.6M | $124.4M | $122.5M | $111.1M | $102.5M |
| Equity | $258.3M | $247.1M | $242.7M | $216.0M | $195.1M | $174.1M | $154.4M | $256.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.1M | $-5.0M | $-24.1M | $-17.9M | $-33.3M | $-12.1M | $-31.2M | $-22.1M |